OnKure Therapeutics (NASDAQ:OKUR) Downgraded by Wall Street Zen to Sell

Key Points

• Wall Street Zen downgraded OnKure Therapeutics from hold to sell, adding to a mixed analyst picture that now includes one Buy, two Hold, and one Sell rating.
• The stock has a consensus rating of Hold with a $27.00 price target, though several firms recently adjusted their views, including HC Wainwright cutting its target from $34 to $27 and JonesTrading downgrading the stock to Hold.
• OnKure recently reported a wider-than-expected quarterly loss, posting EPS of ($1.11) versus the estimate of ($0.74), while shares traded around $3.91 with a market cap of about $53.45 million.

OnKure Therapeutics (NASDAQ:OKUR - Get Free Report) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Saturday.

Several other equities research analysts also recently weighed in on the company. HC Wainwright cut their price objective on OnKure Therapeutics from $34.00 to $27.00 and set a "buy" rating on the stock in a report on Monday, March 16th. JonesTrading downgraded OnKure Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Thursday. Finally, Weiss Ratings raised OnKure Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, April 24th. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $27.00.

OnKure Therapeutics Stock Performance

Shares of OKUR stock opened at $3.91 on Friday. The stock's fifty day moving average price is $4.10 and its two-hundred day moving average price is $3.32. The company has a market cap of $53.45 million, a PE ratio of -0.90 and a beta of 0.36. OnKure Therapeutics has a fifty-two week low of $1.70 and a fifty-two week high of $5.38.

OnKure Therapeutics (NASDAQ:OKUR - Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported ($1.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.37). On average, equities analysts predict that OnKure Therapeutics will post -2.84 EPS for the current fiscal year.

Institutional Trading of OnKure Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Hsbc Holdings PLC bought a new stake in OnKure Therapeutics in the 4th quarter valued at about $58,000. XTX Topco Ltd bought a new stake in OnKure Therapeutics in the 4th quarter valued at about $52,000. ADAR1 Capital Management LLC bought a new stake in OnKure Therapeutics in the 4th quarter valued at about $2,941,000. Kotler Kevin bought a new stake in OnKure Therapeutics in the 4th quarter valued at about $573,000. Finally, Barclays PLC increased its position in OnKure Therapeutics by 4,286.8% in the 4th quarter. Barclays PLC now owns 27,242 shares of the company's stock valued at $79,000 after buying an additional 26,621 shares in the last quarter. 90.98% of the stock is owned by institutional investors.

About OnKure Therapeutics

OnKure Therapeutics, Inc NASDAQ: OKUR is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company's lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.